At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
AZR-MD-001 Active +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability and Pharmacodynamics of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)
In Brief
A Phase 2 clinical trial evaluating AZR-MD-001 Active and AZR-MD-001 Vehicle for Meibomian Gland Dysfunction. Completed, enrolled 31 participants across 5 sites in 2 countries.
Detailed Summary
AZ202001 is a multicenter study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeibomian Gland Dysfunction
CountriesAustralia, New Zealand
CollaboratorsAvania
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartJul 2020
Primary CompletionJan 2021
TodayJul 2026
First PostedMay 18, 2020
Enrollment StartJul 17, 2020
Primary CompletionJan 6, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.1 years ago
Interventions
AZR-MD-001 Activedrug
AZR-MD-001 is an active ophthalmic ointment
AZR-MD-001 Vehicledrug
AZR-MD-001 is a vehicle ophthalmic ointment